A case of progressive multifocal leukoencephalopathy (PML) associated with natalizumab (Tysabri, Biogen) therapy has been reported in a patient with multiple sclerosis (MS) who had tested negative for JC virus (JCV) antibodies just 2 weeks before symptoms developed.
Commenting on the case for Medscape Medical News, Jeffrey Cohen, MD, Cleveland Clinic, Ohio, said this case illustrates two important points. "First, although negative JCV serology is reassuring and lessens the risk of PML, there is a low but finite false-negative rate," he said. "Second, any new MRI lesion or apparent relapse in a patient on Tysabri is suspicious, particularly with prolonged treatment."
Please continue to get monitored and talk to your neurologist about your current risk(s) factor(s).
http://www.medscape.com/viewarticle/857293
**Link requires a membership to Medscape to view**
Commenting on the case for Medscape Medical News, Jeffrey Cohen, MD, Cleveland Clinic, Ohio, said this case illustrates two important points. "First, although negative JCV serology is reassuring and lessens the risk of PML, there is a low but finite false-negative rate," he said. "Second, any new MRI lesion or apparent relapse in a patient on Tysabri is suspicious, particularly with prolonged treatment."
Please continue to get monitored and talk to your neurologist about your current risk(s) factor(s).
http://www.medscape.com/viewarticle/857293
**Link requires a membership to Medscape to view**
Comment